Latest Headlines

1. VedTechBio Unveils Next-Gen Drug Discovery AI; Partners With AlphaMeld In Multi-Therapy Collaboration 7/31/2025

   VedTechBio Research Pvt. Ltd., a pioneer in AI-driven drug discovery, today announced major enhancements to its RxAgentAI™ platform cutting drug discovery timelines in half alongside a strategic collaboration with AlphaMeld Corporation to co-develop multiple therapies for metabolic and rare diseases.

2. Felycin-CA1 (Sirolimus Delayed-Release Tablets) Is The First And Only Drug FDA Approved For The Management Of Ventricular Hypertrophy In Cats With Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting As Many As One In Seven Cats 7/30/2025

   PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide.

3. Actio Biosciences Announces U.S. FDA Clearance Of Investigational New Drug Application And Fast Track Designation For ABS-1230, A KCNT1 Inhibitor For The Treatment Of KCNT1-Related Epilepsy 7/30/2025

   Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application and granted Fast Track designation for ABS-1230, an expected first-in-class, orally administered small molecule KCNT1 inhibitor, for the treatment of KCNT1-related epilepsy.

4. EuMentis Therapeutics Receives U.S. FDA Clearance Of IND Application For EM-221, A Novel PDE10A Inhibitor For Schizophrenia 7/30/2025

   EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions, today announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of EM–221, the company's investigational phosphodiesterase 10A (PDE10A) inhibitor, in patients with schizophrenia.

5. BON Launches AI-Powered New Drug Research And Development 7/30/2025

   Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced the official launch of its AI-driven drug research and development (R&D) business.

6. BioDuro And Atombeat Announce Partnership To Launch An AI-Powered Platform For Accelerated Peptide Drug Discovery 7/30/2025

   BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO), and Atombeat Inc., a leading force in AI for drug discovery, today announced a strategic collaboration to an AI powered platform for accelerated peptide drug discovery.

7. Alpha Cognition Announces Partner China Medical System Has NDA Accepted In China For The Review Of ZUNVEYL (Benzgalantamine) For Alzheimer's Disease 7/29/2025

   Alpha Cognition Inc. (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced China Medical System Holdings Limited (CMS) New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration of China (NMPA) for review for the treatment of mild-to-moderate Alzheimer’s dementia.

8. Transforming Drug Development With Groundbreaking Organ-On-Chip Tech 7/29/2025

   An international team of researchers supported by the EU-funded UNLOOC(opens in new window) project is developing organ-on-chip (OOC) systems that simulate human organ responses, providing faster, safer and more reliable drug testing alternatives.

9. SLAS Discovery: Advancing Tools For Cancer Fibrosis And Drug Discovery 7/29/2025

   Volume 34 of SLAS Discovery includes two original research articles, one short communication and one entry in the upcoming Special Issue on EUOS/SLAS Joint Challenge: Compound Solubility.

10. Making Medicine Out Of Millipedes 7/29/2025

    Millipedes get a bad rap — their many legs put people off and could classify them as “creepy crawly.” But these anthropods’ secretions could hold the key to new drug discovery for the treatment of neurological diseases and pain.